A fundamental shift in drug development strategies is taking place. Traditionally the focus of pharmaceutical companies was on a small portfolio of "blockbuster" products based on epidemiological studies in large patient cohorts. Nowadays, the trend is towards creating a host of more targeted therapies with higher efficacy in smaller patient groups.
CAVΛDIS™ business strategy
This move to personalized medicine
is fully in line with CAVΛ
DIS™ business strategy to generate a strong portfolio of cardiovascular biomarkers to be used as risk stratification tool for developing molecular diagnostics and as surrogate marker of efficacy in clinical trials. This approach is especially required in the field of atherosclerosis, since progression of the disease is slow and hard clinical endpoint studies requiring large patient numbers are extremely expensive for pharmaceutical companies. On average a "blockbuster" drug costs $1 billion to develop over a period of up to 12 years. To increase technical success rate and to reduce drug development time and costs, CAVΛ
DIS™ biomarkers may be used as surrogate endpoint in clinical trials.
Personalized medicine is all about the individual, making use of distinct differences between patients and treatment responses. The ability to identify the right patient, provide the right therapy and obtain a consistent good clinical outcome is our ultimate goal. CAVΛ
DIS™ clinical biomarkers can be applied to target the "positive responders" for new and existing drug treatments. Biomarker can subsequently be used as companion diagnostics and are expected to play an increasingly important role in reimbursement policies.